Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

Also called NCT03087773

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 476 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03087773
Main results
  • Empagliflozin in acute myocardial infarction: the EMMY trial European heart journal, 2022-11-01 DOI, PubMed 36036746, PMC9622301 In the PMC Open Access subset under CC BY-NC.
Other papers using this trial's data
  • Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, 2024 DOI, PubMed 37236318
  • Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial Clinical research in cardiology : official journal of the German Cardiac Society, 2025-05 DOI, PubMed 39297940, PMC12058928 In the PMC Open Access subset under CC BY.
  • Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial Cardiovascular diabetology, 2023-07-05 DOI, PubMed 37407956, PMC10324245 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03087773. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-11 (actual); primary completion 2022-05-03 (actual). Results posted on 2024-08-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
Acronym
EMMY
Condition
Acute Myocardial Infarction
Intervention (Drug)
Empagliflozin 10 mg
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Medical University of Graz (class: other)
Collaborator
United Arab Emirates University (class: other)
Collaborator
Medical University of Vienna (class: other)
Collaborator
Landeskrankenhaus Feldkirch (class: other)
Collaborator
Paracelsus Medical University (class: other)
Collaborator
Hospital Rudolfstiftung (class: other)
Collaborator
Klinikum Klagenfurt am Wörthersee (class: other)
Collaborator
Barmherzige Brüder Eisenstadt (class: other)
Collaborator
Cardinal Schwarzenberg Hospital (class: other)
Collaborator
Johannes Kepler University of Linz (class: other)
Collaborator
Landesklinikum Sankt Polten (class: other)
Collaborator
Landeskrankenhaus II Graz West (class: other)

Record details

Record id
cardio:ct-nct03087773
Content hash
b6729edc81c1bc42e9a073966b62a96166b6d90ad28657189e8cecc81f87a204